Ep. 71: Precision Medicine Revolution – Glen de Vries (Co-CEO Medidata)

Health Unchained

Ep. 71: Precision Medicine Revolution – Glen de Vries (Co-CEO Medidata)

Glen de Vries, is co-founder of Medidata, which w…
August 30, 2020

Ep. 71: Precision Medicine Revolution – Glen de Vries (Co-CEO Medidata)

Glen de Vries, is co-founder of Medidata, which was acquired by Dassault Systems for $6B in 2019. Glen is co-founder and co-CEO of Medidata, the most-used platform for clinical trials around the world. Glen has been driving Medidata’s mission since the company’s inception in 1999, “powering smarter treatments and healthier people”. He has recently authored a book called “The Patient Equation: The Precision Medicine Revolution in the Age of Covid-19 and Beyond” where he describes how the digitization of healthcare data will create massive opportunities for personalized medicine.

Company Homepage:

Disclaimer: Remember, the Health Unchained podcast is for informational and entertainment purposes only and we are not providing any sort of legal, financial, or medical advice. Please do your own research and due diligence before making any important decisions related to these matters.

Show Notes

•Glen’s journey from the lab to starting Medidata
•Healthcare technology innovation and adoption
•Opening up the aperture for better problem solving
•Glen’s New book – The Patient Equation – (all royalties donated to Conquer Cancer, the ASCO (American Society of Clinical Oncology) Foundation).
•Clinical research innovation
•Trends in COVID-19 Clinical Trials/Studies – Lessons for the future?
•How can we develop a healthcare system that aligns with the promise precision medicine?
•The Importance of incentives in healthcare systems
•How can smart devices and wearables change the way doctors practice medicine?
•DoD – Device on Dog problem
•Will wearables improve patient adherence monitoring during clinical research?
•What is the value/benefits of collecting personal healthcare data over time?
•Gattaca (the movie) and it’s relation to healthcare data
•What are the limits of technology for clinical trials research?
•What impact do the big tech players have on the clinical trials industry?
•What is Medidata’s roadmap for the rest of 2020 and 2021?
•Who are the people who have been your biggest influences?
•When do you expect to go to space? –
•Final takeaways

News Corner

On August 26, 2020, in an effort to provide faster Covid-19 test results, the FDA authorized an emergency use of a rapid antigen test that can only be used by authorized labs and patient care settings. To be clear, the BinaxNOW™ COVID-19 Ag Test Card EUA has not been FDA cleared or approved for broad consumer use.
A day after Abbott received this emergency FDA approval of its 15-minute COVID-19 test, HHS has awarded it a $760 million contract to produce 150 million tests, the department said this week. The HHS said the tests may be deployed to schools and other “special needs” populations.
Healthcare providers using Abbott’s test will swab a patient’s nose, transfer the sample to a test card. Results become available In just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5% in clinical study. Abbott says they will ship tens of millions of tests in September, ramping to 50 million tests a month at the beginning of October.

Health Unchained Links

Bert’s Blockchain and Healthcare Weekly Newsletter:

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Network Sponsors and Advertisers

Event and Media Partners

Buffer LinkedIn WhatsApp